How to Get Enclomiphene Citrate in Wisconsin

What Enclomiphene Citrate Is and Why Wisconsin Men Use It

Enclomiphene citrate is the trans-isomer of clomiphene and acts as a selective estrogen receptor modulator (SERM) at the hypothalamic-pituitary axis. It stimulates endogenous gonadotropin release, raising testosterone without suppressing spermatogenesis, which distinguishes it sharply from exogenous testosterone replacement therapy. Wisconsin clinicians prescribe it off-label for secondary hypogonadism, a condition in which low testosterone results from inadequate pituitary signaling rather than primary testicular failure.

The clinical rationale is well-supported. Kim et al. (BJU Int, 2016, N=180) demonstrated that enclomiphene citrate 12.5 mg and 25 mg daily normalized serum testosterone in men with secondary hypogonadism while preserving sperm concentration, compared with transdermal testosterone gel, which suppressed sperm counts significantly 1. A separate phase III study published in the same journal showed mean total testosterone rose from 247 ng/dL at baseline to 416 ng/dL after 12 weeks of 12.5 mg daily, with LH and FSH remaining within or above reference range throughout 1.

The FDA reviewed enclomiphene under the trade name Androxal; the pharmacology and safety data from those clinical submissions inform current compounding practice even though no branded product is commercially available today 2. Wisconsin prescribers rely on 503A compounding pharmacies to prepare each patient-specific supply, which is fully lawful under federal and state pharmacy law provided a valid prescription exists 3.

The Wisconsin Legal Framework for Prescribing and Dispensing

Wisconsin permits telehealth prescribing of controlled and non-controlled substances provided the prescriber holds a current Wisconsin license and completes a good-faith evaluation. Enclomiphene is not a controlled substance, so telehealth prescribing carries fewer restrictions than Schedule III or IV medications.

Under Wis. Stat. 448.975, nurse practitioners with collaborative agreements and physician assistants under physician supervision may prescribe prescription-only drugs including compounded preparations 4. Pharmacists at 503A facilities compound enclomiphene to patient-specific orders; 503B outsourcing facilities are not permitted to compound office-use stock of this compound without FDA registration, but 503A dispensing directly to the patient is straightforward and common 3.

The Wisconsin Pharmacy Examining Board licenses compounding pharmacies independently of whether they also dispense commercially manufactured drugs. Any pharmacy holding a current Wisconsin resident or non-resident pharmacy permit may receive and fill a Wisconsin enclomiphene prescription, as long as the compounding is performed according to USP 795 standards 5.

Required Labs Before Your First Prescription

Responsible Wisconsin prescribers will not write an enclomiphene prescription without a diagnostic hormone panel. This protects patients and satisfies documentation requirements for Wisconsin Medicaid prior authorization.

The minimum panel includes:

• Total testosterone (morning draw, 7 a.m. to 10 a.m., two separate occasions at least one week apart)
• LH and FSH (to confirm secondary rather than primary hypogonadism; LH <4 IU/L with low testosterone points to secondary etiology)
• Estradiol (baseline before introducing a SERM; elevated estradiol may require monitoring frequency adjustment)
• SHBG (sex hormone-binding globulin; high SHBG can cause total testosterone to appear normal while free testosterone is low)
• Prolactin (hyperprolactinemia is a reversible cause of secondary hypogonadism that enclomiphene will not fix)
• CBC and comprehensive metabolic panel (safety baseline per Endocrine Society guidelines) 6
• PSA (for men over 40; enclomiphene modestly raises endogenous androgen levels, and baseline PSA context is standard of care) 6

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness; measure testosterone only in men with consistent signs and symptoms" 6. Following this guidance means your Wisconsin provider should review symptom history alongside lab values, not labs alone.

Quest Diagnostics and LabCorp both maintain draw sites throughout Wisconsin, including Milwaukee, Madison, Green Bay, Racine, and Kenosha. Most telehealth platforms generate a lab order you take to any local draw site; results return digitally to the prescriber within 24 to 72 hours 7.

Step-by-Step: Getting Your Enclomiphene Prescription in Wisconsin

Getting from symptom recognition to medication in hand involves four discrete steps. Each has a defined timeline.

Step 1. Online consultation (Day 1) Choose a Wisconsin-licensed telehealth provider or in-person men's health clinic. The intake form collects symptom history, prior testosterone results if available, medications, and a brief cardiovascular history. Video consultations typically run 20 to 30 minutes. The provider orders baseline labs at this visit 8.

Step 2. Lab draw and result review (Days 2 to 5) Visit a Wisconsin draw site with your digital lab order. Results reach the provider in one to three business days. The provider interprets the hormone panel, rules out primary hypogonadism or pituitary pathology, and confirms enclomiphene is the appropriate agent. If prolactin is elevated above 25 ng/mL, the provider may order a pituitary MRI before initiating therapy 6.

Step 3. Prescription issued and sent to pharmacy (Day 4 to 6) The prescriber sends a written prescription electronically to a licensed Wisconsin 503A compounding pharmacy. The script specifies dose (commonly 12.5 mg or 25 mg), capsule or tablet form, quantity, and refill authorization. No DEA number is required since enclomiphene is not a scheduled substance.

Step 4. Dispensing and shipping (Days 5 to 10) The pharmacy compounds the batch, performs quality testing, and ships directly to your Wisconsin address. Most licensed compounders use two-day tracked shipping. First-time orders sometimes take a day longer due to patient profile setup.

Telehealth Providers in Wisconsin Prescribing Enclomiphene

Wisconsin adopted an updated telehealth standard of care law in 2021 that explicitly permits prescribing after a synchronous audio-video encounter, removing the prior requirement for an in-person baseline visit for non-controlled substances 4. This means a Wisconsin man living in rural areas such as the Northwoods, the Fox Valley, or the Driftless region can access the same enclomiphene evaluation available in Milwaukee without a four-hour round trip.

Platforms prescribing enclomiphene to Wisconsin residents typically charge a consultation fee of $75 to $200, separate from the compounded medication cost. Compounded enclomiphene 12.5 mg to 25 mg runs approximately $60 to $120 per month depending on the pharmacy and dose. Insurance reimbursement for the drug itself is uncommon outside Medicaid prior authorization, but the consultation visit may apply toward a deductible under an HSA-eligible plan 9.

Any telehealth provider treating Wisconsin patients must hold an active Wisconsin medical or advanced practice license. Confirm licensure at the Wisconsin Department of Safety and Professional Services (DSPS) license lookup before booking.

Wisconsin Medicaid and Prior Authorization

Wisconsin Medicaid (ForwardHealth) lists enclomiphene citrate as a covered compound for secondary hypogonadism when prescribed off-label, subject to prior authorization (PA). The PA packet requires specific documentation.

Required PA documentation typically includes:

1. Diagnosis code (E29.1, testicular hypofunction) with clinical notes confirming secondary etiology
2. Two morning total testosterone levels below 300 ng/dL on separate dates
3. LH and FSH results confirming secondary pattern (low-normal LH despite low testosterone)
4. Statement of medical necessity explaining why FDA-approved testosterone products are not appropriate (e.g., fertility preservation, patient preference against spermatogenesis suppression)
5. Provider attestation that the 503A pharmacy is Wisconsin-licensed

The Endocrine Society guideline threshold for initiating therapy is total testosterone below 300 ng/dL confirmed on two morning measurements, combined with signs and symptoms of hypogonadism 6. That threshold aligns with the ForwardHealth PA criteria, which means a properly documented case should clear PA without a supplemental appeal in most instances.

PA processing in Wisconsin Medicaid takes five to ten business days for standard review. Expedited review (72 hours) is available when a provider certifies that delay would adversely affect the patient's condition 10.

503A Compounding Pharmacies and Shipping to Wisconsin

No FDA-approved commercial enclomiphene product is currently marketed in the United States for male hypogonadism. Androxal (enclomiphene citrate) received an FDA Complete Response Letter rather than full approval; its NDA (NDA 022529) is publicly searchable in the FDA's drug database 2. Because of this regulatory status, Wisconsin patients obtain enclomiphene exclusively through 503A compounding pharmacies that prepare drug products in response to individual patient prescriptions.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare enclomiphene for an individual patient without an approved NDA, provided the pharmacy is state-licensed, the drug is not on the FDA's list of drugs withdrawn from sale for safety reasons, and the preparation follows USP 795 standards 3. Enclomiphene's raw API (active pharmaceutical ingredient) is commercially available from FDA-registered suppliers, satisfying the supply-chain traceability requirement 5.

Wisconsin-licensed non-resident pharmacies in states such as Florida, Texas, and Colorado commonly ship compounded enclomiphene to Wisconsin addresses. The receiving state (Wisconsin) allows interstate shipment provided the originating pharmacy holds a Wisconsin non-resident pharmacy permit from the DSPS Pharmacy Examining Board. Confirm this permit before placing an order, since shipping a compounded prescription drug across state lines without the appropriate license is a federal violation regardless of the patient's intent.

Monitoring After Starting Enclomiphene in Wisconsin

Enclomiphene is not a set-and-forget prescription. Wisconsin providers following Endocrine Society and American Urological Association guidance typically schedule follow-up labs at six weeks and three months after starting therapy 6 11.

The six-week panel includes total testosterone, LH, FSH, and estradiol. The purpose is to confirm LH is rising appropriately (typically to 3 to 12 IU/L) and that testosterone is trending toward the 400 to 700 ng/dL target range. If estradiol climbs above 40 pg/mL with symptoms (nipple tenderness, water retention), a prescriber may add a low-dose aromatase inhibitor such as anastrozole 0.5 mg twice weekly 12.

The three-month panel adds SHBG, CBC, and PSA for men over 40. At this point, a prescriber evaluating full response can decide whether to continue the current dose, titrate from 12.5 mg to 25 mg, or consider whether the patient's hypogonadism is responding well enough to justify ongoing therapy 1.

Kim et al. (2016) reported that 70% of men on 25 mg enclomiphene maintained testosterone above 300 ng/dL at 12 weeks without any change to sperm parameters 1. That sperm preservation data is the primary reason fertility-aware Wisconsin men and their reproductive endocrinologists favor enclomiphene over topical or injectable testosterone 13.

Transferring an Out-of-State Enclomiphene Prescription to Wisconsin

Men relocating to Wisconsin with an active enclomiphene prescription from another state face a specific regulatory situation. Enclomiphene is not a controlled substance, so federal law does not restrict transfer across state lines the way Schedule II drugs are restricted. However, a Wisconsin pharmacy can only fill a prescription written by a provider licensed in Wisconsin or a state with reciprocal prescriptive authority.

The cleanest solution: book a telehealth visit with a Wisconsin-licensed provider, share your prior lab results (if they are fewer than six months old), and receive a new Wisconsin prescription. Most platforms accept uploaded PDFs of prior lab work, meaning you may not need to repeat the full diagnostic panel if your existing results are recent and complete 8.

If your out-of-state prescriber holds a Wisconsin telemedicine license, they may simply send the prescription directly to a Wisconsin-licensed compounding pharmacy without a transfer. Confirm licensure via DSPS before assuming this option is available.

Side Effects and Contraindications Wisconsin Patients Should Know

Enclomiphene's side effect profile reflects its SERM mechanism. The most common adverse effects reported in clinical trials are visual disturbances (blurred vision or light sensitivity, occurring in roughly 1 to 2% of users), mood changes, and hot flashes 1. Visual symptoms require prompt discontinuation and ophthalmologic evaluation, consistent with clomiphene-class labeling 2.

Absolute contraindications include active liver disease, known hypersensitivity to clomiphene or enclomiphene, and any hormone-sensitive malignancy. Relative contraindications include primary hypogonadism (Klinefelter syndrome, bilateral orchidectomy), because a drug that works by stimulating the pituitary cannot compensate for absent testicular response 6.

Men with untreated hyperprolactinemia should address the prolactin excess with cabergoline or bromocriptine before adding enclomiphene, since elevated prolactin blunts the pituitary response to SERM stimulation 14. Untreated sleep apnea is another factor to address before ascribing low testosterone solely to secondary hypogonadism, given that apnea suppresses nocturnal LH pulsatility 15.

Cost Comparison: Enclomiphene vs. Testosterone in Wisconsin

Wisconsin men comparing enclomiphene to traditional TRT should weigh both direct and indirect costs.

Compounded enclomiphene 12.5 mg to 25 mg daily costs roughly $60 to $120 per month through a Wisconsin-accessible 503A pharmacy. Generic testosterone cypionate 200 mg/mL vials (self-injected weekly) run $20 to $60 per month at Wisconsin retail pharmacies when covered by commercial insurance, but the injections require supplies, and discontinuation causes a transient testosterone crash as endogenous production restarts slowly 16.

Topical testosterone gel (e.g., AndroGel 1.62%) costs $300 to $500 per month without insurance. Transfer risk to partners and children and the permanent suppression of sperm production add non-financial costs that matter to Wisconsin men who have not yet completed their families 13.

From a pure fertility standpoint, Kim et al. showed enclomiphene preserved mean sperm concentration at 33 million per mL at 16 weeks versus a decline to 4.6 million per mL in the testosterone gel arm, a difference that is clinically significant for men planning conception 1.

Finding a Wisconsin Provider: What to Ask Before You Book

Not every Wisconsin telehealth or men's health clinic has experience with enclomiphene. Ask these specific questions before committing to a provider:

1. "Do you prescribe enclomiphene citrate, or only testosterone replacement?"
2. "Which 503A compounding pharmacies do you work with, and are they Wisconsin-permitted?"
3. "Will you order the full baseline panel including LH, FSH, and prolactin?"
4. "What is your follow-up protocol, and does it include a six-week hormone recheck?"
5. "Can you submit a prior authorization to Wisconsin ForwardHealth if I'm on Medicaid?"

A provider who cannot answer questions two through five in specific terms may lack the compounding and payer experience to manage enclomiphene therapy effectively 8.

The American Urological Association's 2023 Guideline on Testosterone Deficiency notes that clinicians should "discuss the potential impact of testosterone therapy on fertility" and present alternatives including SERMs for patients who desire fertility preservation 11. That language makes enclomiphene a guideline-supported option, not an experimental workaround, for appropriately selected Wisconsin men.